Epizyme, Inc., a clinical-stage company developing novel epigenetic therapies, announced today that updated efficacy and safety data from the fully enrolled cohort of epithelioid sarcoma (ES) patients in its ongoing Phase 2 trial of tazemetostat will be presented in a poster discussion session at the European Society for Medical Oncology (ESMO) 2018 Congress to be held October 19-23 in Munich, Germany.
![Design thinking als contentmarketeer inzetten [voorbeelden & tips]](https://www.pharmamarketeer.nl/wp-content/uploads/2024/11/business-team-working-in-a-start-up-office-2023-11-27-05-22-22-utc-1-80x60.jpg)
Reageer